Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110015/S011

13C-Gastric Emptying Breath Test (GEBT), 13C-Spirulina Gastric Emptying Breath Test (GEBT), 13C-GEBT

Advanced Breath Diagnostics · Decision date Jul 21, 2025

FDA DECISIONP110015/S011

What did the FDA approve?

FDA records P110015/S011 as a supplement to PMA P110015, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jul 21, 2025.

FDA approval order statement

approval for a manufacturing site located at Spirulina Production Facility (also known as API ProductionFacility), 318 Seaboard Lane, Suite 313, Franklin, TN 37067, USA, for lyophilization of 13C-Spirulina
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Clinical Chemistry
Decision date
Jul 21, 2025
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110015/S011
Regulatory pathway
PMA supplement
Product code
PGE
Decision code
APPR
Decision date
Jul 21, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Gastric Emptying Breath Test.

Product code
PGE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110015/S011 received

    Application receipt date recorded by FDA.

  2. P110015/S011 · FDA decision

    Normal 180 Day Track No User Fee

  3. P110015/S012 · Related supplement

    13C-Spirulina Gastric Emptying Breath Test (GEBT)

Timeline entries are records held by MedtechLedger for P110015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110015

Product / regulatory recordCompanyPathwayDecision dateSource
Advanced Breath DiagnosticsPMA supplementApr 24, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Advanced Breath Diagnostics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
105 Westpark Dr. Suite 150, Brentwood, TN, 37027

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records